Updated and expanded text Nov 4th: Lung cancer research funded by national clinical research program KLINBEFORSK

Åslaug Helland
Åslaug Helland

Åslaug Helland, head of the Translational studies on solid tumours reserach group at the Department of Cancer Genetics at Oslo University Hospital, receives 14,2 mill NOK from The national programme for clinical therapy research - KLINBEFORSK.
The supported project is entitled "Durvalumab After RadioTherapy – the DART-study". The purpose is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.

NB: text expanded on Nov 4th, with more details